BioMarin Pharmaceutical Lowers FY2026 Adj EPS Guidance from $4.95-$5.15 to $4.85-$5.05 vs $4.43 Est; Raises FY2026 Sales Guidance from $3.325B-$3.425B to $3.825B-$3.925B vs $3.635B Est

Benzinga Newsdesk www.benzinga.com Negative 87.1%

Neg 87.1% Neu 0% Pos 0%

Comments

No comments yet. Be the first!